Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Estimating the effect size of the 15Q11.2 BP1–BP2 deletion and its contribution to neurodevelopmental symptoms: recommendations for practice

Aia Elise Jønch 1 Elise Douard 2 Clara Moreau 3 Anke van Dijck 4 Marzia Passeggeri 5 Frank Kooy 4 Jacques Puechberty 6, 7 Carolyn Campbell 8 Damien Sanlaville 9, 10 Henrietta Lefroy 8 Sonia Richetin 5 Aurelie Pain 5 David Geneviève 11, 7 Usha Kini 12, 8 Cédric Le Caignec 13, 14 James Lespinasse 15 Anne-Bine Skytte 16 Bertrand Isidor 17 Christiane Zweier 18 Jean-Hubert Caberg 19 Marie-Ange Delrue 20, 2 Rikke Steensbjerre Møller 21 Anders Bojesen 1 Helle Hjalgrim 1 Charlotte Brasch-Andersen 1 Emmanuelle Lemyre 2 Lilian Bomme Ousager 1 Sébastien Jacquemont 2
Abstract : BACKGROUND: The 15q11.2 deletion is frequently identified in the neurodevelopmental clinic. Case-control studies have associated the 15q11.2 deletion with neurodevelopmental disorders, and clinical case series have attempted to delineate a microdeletion syndrome with considerable phenotypic variability. The literature on this deletion is extensive and confusing, which is a challenge for genetic counselling. The aim of this study was to estimate the effect size of the 15q11.2 deletion and quantify its contribution to neurodevelopmental disorders. METHODS: We performed meta-analyses on new and previously published case-control studies and used statistical models trained in unselected populations with cognitive assessments. We used new (n=241) and previously published (n=150) data from a clinically referred group of deletion carriers. 15q11.2 duplications (new n=179 and previously published n=35) were used as a neutral control variant. RESULTS: The deletion decreases IQ by 4.3 points. The estimated ORs and respective frequencies in deletion carriers for intellectual disabilities, schizophrenia and epilepsy are 1.7 (3.4%), 1.5 (2%) and 3.1 (2.1%), respectively. There is no increased risk for heart malformations and autism. In the clinically referred group, the frequency and nature of symptoms in deletions are not different from those observed in carriers of the 15q11.2 duplication suggesting that most of the reported symptoms are due to ascertainment bias. CONCLUSIONS: We recommend that the deletion should be classified as 'pathogenic of mild effect size'. Since it explains only a small proportion of the phenotypic variance in carriers, it is not worth discussing in the developmental clinic or in a prenatal setting.
Liste complète des métadonnées
Contributeur : Nathalie Salvy-Cordoba <>
Soumis le : mardi 5 mai 2020 - 12:12:50
Dernière modification le : vendredi 15 mai 2020 - 12:22:10

Lien texte intégral



Aia Elise Jønch, Elise Douard, Clara Moreau, Anke van Dijck, Marzia Passeggeri, et al.. Estimating the effect size of the 15Q11.2 BP1–BP2 deletion and its contribution to neurodevelopmental symptoms: recommendations for practice. Journal of Medical Genetics, BMJ Publishing Group, 2019, 56 (10), pp.701-710. ⟨10.1136/jmedgenet-2018-105879⟩. ⟨hal-02563409⟩



Consultations de la notice